HC Wainwright set a $23.00 price target on Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) in a research note published on Wednesday, April 17th, TipRanks reports. The firm currently has a buy rating on the stock.
Separately, Zacks Investment Research downgraded shares of Rexahn Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, January 8th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Rexahn Pharmaceuticals has an average rating of Buy and an average target price of $42.67.
NYSEAMERICAN:RNN traded down $0.09 during trading hours on Wednesday, hitting $5.75. 8,486 shares of the stock traded hands, compared to its average volume of 166,844. Rexahn Pharmaceuticals has a fifty-two week low of $4.75 and a fifty-two week high of $28.56.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its holdings in shares of Rexahn Pharmaceuticals by 11.7% in the first quarter. BlackRock Inc. now owns 232,614 shares of the company’s stock valued at $119,000 after purchasing an additional 24,436 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Rexahn Pharmaceuticals in the first quarter valued at approximately $43,000. Virtu Financial LLC increased its holdings in shares of Rexahn Pharmaceuticals by 36.2% in the first quarter. Virtu Financial LLC now owns 62,036 shares of the company’s stock valued at $32,000 after purchasing an additional 16,481 shares in the last quarter. Finally, CVI Holdings LLC acquired a new stake in shares of Rexahn Pharmaceuticals in the fourth quarter valued at approximately $1,439,000.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer; and RX-5902 that is in Phase IIa clinical trials to treat patients with metastatic triple negative breast cancer.
Featured Story: How is net asset value different from market price?
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.